TITLE

HORMONAL CONTRACEPTION AND THROMBOSIS

AUTHOR(S)
Costescu, Dustin J.; Waddington, Ashley; Rosendaal, Frits R.; Helmerhorst, Frans M.
PUB. DATE
April 2013
SOURCE
BMJ: British Medical Journal;4/20/2013, Vol. 346 Issue 7904, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article ``Is an EMA review on hormonal contraception and thrombosis needed?'' by Helmerhorst and Rosendaal in the March 7, 2013 issue.
ACCESSION #
87386289

 

Related Articles

  • Meta-analysis of thrombosis risk with oral contraceptives.  // Reactions Weekly;9/28/2013, Issue 1471, p4 

    The article focuses on the meta-analysis of thrombosis risk associated with oral contraceptives and reports that the risk of venous thrombosis was increased in individuals taking oral contraceptives as compared to non-users.

  • Drospirenone: increased risk of blood clots.  // WHO Drug Information;2011, Vol. 25 Issue 4, p360 

    No abstract available.

  • Pill scare linked to rise in abortions. Dillner, Luisa // BMJ: British Medical Journal (International Edition);4/20/96, Vol. 312 Issue 7037, p996 

    Reports on the possible increase of abortions in Great Britain in the wake of the government's 1995 warning on the role of certain contraceptive pills in increasing the risk of deep vein thrombosis. Number of abortions carried out by the British Pregnancy Advisory Service (BPAS); BPAS' view...

  • The risk of arterial thrombosis increases with the use of combined oral contraceptives. Lidegaard, √ėjvind // Evidence Based Medicine;Feb2016, Vol. 21 Issue 1, p38 

    The article reflects on a research related to increased risks of arterial thrombosis with the use of combined oral contraceptives (COC). Topics discussed include dependence of the risks on progestogen levels, influence of COC towards risks of thrombotic stroke resulting through venous...

  • Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Kemmeren, Jeanet M; Algra, Ale; Grobbee, Diederick E // BMJ: British Medical Journal (International Edition);7/21/2001, Vol. 323 Issue 7305, Special section p1 

    Results: The overall adjusted odds ratio for third versus second generation oral contraceptives was 1.7 (95% confidence interval 1.4 to 2.0; seven studies). Similar risks were found when oral contraceptives containing desogestrel or gestodene were compared with those containing levonorgestrel....

  • Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events. Christiansen, S. C.; Cannegieter, S. C.; Koster, T. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p59 

    The article reports focuses on a study on the contribution of male gender, first idiopathic deep venous thrombosis and oral contraception on the occurrence of recurrent venous thrombotic events. Prothrombotic abnormalities however did not appear to play an important role. The study was conducted...

  • Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Lidegaard, Ojvind // BMJ: British Medical Journal (International Edition);4/10/93, Vol. 306 Issue 6883, p956 

    Examines the risk of cerebral thromboembolism in women using low dose oral contraception in Denmark. Association of oral contraceptives with cerebral thromboembolic attacks; Comparison of risks between estrogen and progestogen pills; Effect of age on cerebral thromboembolic attack.

  • The right to know.  // New Scientist;10/28/95, Vol. 148 Issue 2001, p3 

    Editorial. Criticizes the Great Britain's Committee on Safety of Medicines'(CSM) hasty announcement on the effect of contraceptive pills containing gestodene or desogestrel on women. Risk of thrombosis for women who take the pills; Need for CSM to be held accountable for its decisions.

  • FDA schedules review of drospirenone pills.  // Contraceptive Technology Update;Dec2011, Vol. 32 Issue 12, p138 

    The article reports on a decision which the U.S. Food and Drug Administration made to schedule a December 8, 2011 meeting of its Reproductive Health Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to review oral contraceptives containing the progestin drospirenone.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics